![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GSK'S INNOVATIVE ADJUVANT IN CANDIDATE HPV VACCINE (CERVARIXTM) INDUCES STRONGER & SUSTAINED IMMUNE RESPONSE COMPARED TO CONVENTIONAL ADJUVANT
GSK'S INNOVATIVE ADJUVANT IN CANDIDATE HPV VACCINE (CERVARIXTM) INDUCES STRONGER & SUSTAINED IMMUNE RESPONSE COMPARED TO CONVENTIONAL ADJUVANT
The immune response against the virus that causes cervical cancer is stronger and sustained following vaccination with GlaxoSmithKline's (GSK) candidate HPV vaccine formulated with the innovative AS04 adjuvant compared to using the same vaccine formulated with a conventional aluminium salt adjuvant.
Medical
News Today
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct